专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2011227095A Diagnostic method for disorders using copeptin 审中-公开
标题翻译：使用COPEPTIN的疾病诊断方法
公开(公告)号：JP2011227095A
公开(公告)日：2011-11-10
申请号：JP2011168242
申请日：2011-08-01
申请人： B.R.A.H.M.S Gmbh , ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー
发明人： ANDREAS BERGMANN , JOACHIM STRUCK
IPC分类号： G01N33/53 , C07K7/16 , G01N33/74
CPC分类号： G01N33/6893 , G01N33/74 , G01N2333/575 , G01N2333/5757 , Y10S930/15
摘要： PROBLEM TO BE SOLVED: To extremely suppress the use as a biomarker even under optimized samples logistics, as the influence of the degradation occurs rapidly, due to a low in vivo stability of vasopression and the variable results due to the binding to and release from blood platelets.SOLUTION: The use of copeptin as diagnostic maker for determination of the release of vasopressin, especially in connection with disorders associated with non-physiological alternations of vasopressin release from the neurohypophysis, especially for detection and early detection, diagnosing and monitoring of the course of cardiovascular diseases, renal and pulmonary diseases as well as shock, including septic shock, sepsis and diseases/disorders of the central nervous system and neurodegenerative diseases.
摘要翻译：要解决的问题：即使在优化的样品物流下，为了极大地抑制作为生物标志物的用途，由于降解的影响快速发生，由于体内血管扩张的稳定性以及由于与从血小板释放。解决方案：使用copeptin作为诊断剂，用于确定加压素的释放，特别是与神经垂体发生加压素释放的非生理性交替相关的疾病，特别是用于检测和早期检测，诊断和监测血管加压素的诊断和监测心血管疾病，肾脏和肺部疾病以及休克，包括败血性休克，败血症和中枢神经系统疾病/紊乱和神经退行性疾病。版权所有（C）2012，JPO＆INPIT

2. 发明申请

WO2021204984A1 BIOMARKERS FOR THE DIAGNOSIS OF RESPIRATORY TRACT INFECTIONS 审中-公开
公开(公告)号：WO2021204984A1
公开(公告)日：2021-10-14
申请号：PCT/EP2021/059264
申请日：2021-04-09
申请人： B.R.A.H.M.S GMBH
发明人： HAUSMANN, Michael , CURDT, Ingo , GEHRIG, Stefan , DINTER, Christiane
IPC分类号： G01N33/68
摘要： The present invention relates to a method for diagnosing a respiratory tract infection in a subject, comprising determining in a sample from said subject the level of High-Mobility- Group-Protein B1 (HMGB1), and/or determining in a sample from said subject the level of a histone protein, and/or determining in a sample from said subject the level of Insulin-like growth factor binding protein, acid labile subunit (IGFALS), wherein the subject is diagnosed with a bacterial respiratory tract infection when the level of IGFALS is below a predetermined threshold level and/or the level of the histone protein is above a predetermined threshold value, and/or wherein the subject is diagnosed with a respiratory tract infection when the level of HMGB1 is above a predetermined threshold level.

3. 发明申请

WO2019053115A1 PRO-ADM AS A THERAPY MONITORING MARKER FOR CRITCALLY ILL PATIENTS 审中-公开
公开(公告)号：WO2019053115A1
公开(公告)日：2019-03-21
申请号：PCT/EP2018/074722
申请日：2018-09-13
申请人： B.R.A.H.M.S GMBH
发明人： WILSON, Darius
IPC分类号： G01N33/68 , G01N33/74
摘要： The invention relates to a method for therapy monitoring, comprising the prognosis, risk assessment and/or risk stratification of a subsequent adverse event in the health of a patient, comprising providing a sample of said patient, wherein the patient has been diagnosed as being critically ill and medical treatment has been initiated, wherein the sample is isolated from the patient after diagnosis and treatment initiation; determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the likelihood of a subsequent adverse event in the health of said patient. In a preferred embodiment the invention relates to a method comprising additionally determining a level of procalcitonin (PCT) or fragment(s) thereof in a sample isolated from the patient. Preferably, a method of the present invention comprises determining a level of procalcitonin (PCT) or fragment(s) thereof in a first sample isolated from the patient, wherein said first sample is isolated at or before the time point of diagnosis and treatment initiation (time point 0); determining a level of PCT or fragment(s) thereof in a second sample isolated from said patient after diagnosis and treatment initiation; and determining whether a difference in the level of PCT or fragment(s) thereof in the second sample is evident in comparison to the level of PCT or fragment(s) thereof in the first sample.

4. 发明申请

WO2018029213A1 HISTONES AND/OR PROADM AS MARKERS INDICATING ORGAN DYSFUNCTION 审中-公开
标题翻译： HISTONES和/或PROADM作为指示器官功能障碍的标记
公开(公告)号：WO2018029213A1
公开(公告)日：2018-02-15
申请号：PCT/EP2017/070111
申请日：2017-08-08
申请人： B.R.A.H.M.S GMBH
发明人： ZIERA, Tim , DREYER, Frauke , INCAMPS, Anne , KROP, Manne , CHARLES, Pierre-Emmanuel
IPC分类号： G01N33/68 , G01N33/74
摘要： The present invention relates to the diagnosis, prognosis, risk assessment, risk stratification, monitoring, therapy guidance and/or therapy control of organ dysfunction in a subject. The invention relates to a method that comprises determining a level of at least one histone, particularly H2B, H4, H2A and/or H3, in a sample of said subject and wherein said level of at least one histone is indicative of said organ dysfunction. Further, the invention relates to a method that comprises determining a level of proadrenomedullin (proADM), particularly midregional proadrenomedullin (MR-proADM), in a sample of said subject and wherein said level of proADM is indicative of said organ dysfunction. The invention further relates to kits for carrying out the methods of the invention.
摘要翻译：本发明涉及受试者器官功能障碍的诊断，预后，风险评估，风险分层，监测，治疗指导和/或治疗控制。本发明涉及一种方法，其包括测定所述受试者样品中至少一种组蛋白，特别是H2B，H4，H2A和/或H3的水平，并且其中至少一种组蛋白的所述水平指示所述器官功能障碍。此外，本发明涉及一种方法，其包括测定所述受试者的样品中proadrenomedullin（proADM），特别是中间区肾上腺髓质素（MR-proADM）的水平，并且其中所述proADM水平指示所述器官功能障碍。本发明还涉及用于实施本发明方法的试剂盒。

5. 发明申请

WO2015004248A2 AUGURIN IMMUNOASSAY 审中-公开
公开(公告)号：WO2015004248A2
公开(公告)日：2015-01-15
申请号：PCT/EP2014/064840
申请日：2014-07-10
申请人： B.R.A.H.M.S GMBH
发明人： STRUCK, Joachim , ZIERA, Tim
IPC分类号： G01N33/74
CPC分类号： G01N33/74 , C07K16/26 , C07K2317/34 , C12N5/12 , G01N2333/575
摘要： The present invention relates to an immunoassay method for the detection of augurin or a precursor or fragment thereof comprising contacting a sample suspected of comprising augurin or a precursor or fragment thereof with a first and second antibody specific for augurin or a precursor or fragment thereof, wherein said first and second antibodies or antigen-binding fragments or derivatives thereof are specific for epitopes comprised in the sequence spanning amino acids 71 to 107 of pre-augurin according to SEQ ID NO:1.
摘要翻译：本发明涉及用于检测吉非糖苷或其前体或片段的免疫测定方法，其包括将疑似含有宏观神经元或其前体或片段的样品与对于巨核糖蛋白或其前体或片段特异性的第一和第二抗体进行接触，其中所述第一抗体或第二抗体或其抗原结合片段或其衍生物对于跨越根据SEQ ID NO：1的前兆元素的氨基酸71至107的序列中的表位是特异性的。

6. 发明申请

WO2011104238A1 A METHOD FOR DETERMINING A MARKER IN SMALL VOLUME OF A SAMPLE OF A BODILY FLUID 审中-公开
标题翻译：一种确定体液样品小体积标记的方法
公开(公告)号：WO2011104238A1
公开(公告)日：2011-09-01
申请号：PCT/EP2011/052613
申请日：2011-02-22
申请人： B.R.A.H.M.S GMBH , ECKHARDT, Florian
发明人： ECKHARDT, Florian
IPC分类号： G01N21/86
CPC分类号： G01N33/558 , G01N21/8483
摘要： The invention refers to a method for determining a marker in a small volume of a sample of a bodily fluid, the method comprising the steps of: providing a flow test element having a plurality of functional zones (3, 4, 5, 6, 7), the plurality of functional zones (3, 4, 5, 6, 7) being at least partially fluidly connected and comprising an application zone (3) and a testing zone (5) fluidly connected to the application zone (3) and configured for determination of a marker in a bodily fluid and / or a constituent of the bodily fluid, applying a small volume of a liquid sample to the sample application zone (3) of the flow test element, determining a correct test performance, wherein the step of determining correct test performance comprises the steps of measuring at least one optical parameter for one or more functional zones (3; 4; 5; 6; 7), comparing the at least one optical parameter measured to at least one predefined optical parameter assigned to the one or more functional zones (3; 4; 5; 6; 7), and, if the correct test performance is determined, determining the marker in the liquid sample by reading the testing zone (5). Also, a method for determining a correct test performance for a flow test element is provided.
摘要翻译：本发明涉及用于确定体积小样本体液中的标记物的方法，所述方法包括以下步骤：提供具有多个功能区（3）的流量测试元件，多个功能区域（3,4,5,6,7）至少部分地流体连接并且包括施加区域（3）和测试区域（5），所述测试区域（5）流体地连接到（3）并且被配置用于确定体液和/或体液成分中的标记，将小体积液体样品施加到流量测试元件的样品施加区域（3），确定正确的测试性能，其中确定正确测试性能的步骤包括以下步骤：测量一个或多个功能区（3; 4; 5; 6; 7）的至少一个光学参数;将测量的至少一个光学参数分配给一个或多个功能的至少一个预定义的光学参数最终区（3; 4; 5; 6; 7），并且如果确定了正确的测试性能，则通过读取测试区域（5）来确定液体样品中的标记。此外，还提供了确定流量测试元件正确测试性能的方法。

7. 发明申请

WO2021204770A1 PRO-ADRENOMEDULLIN FOR PROGNOSING DISEASE PROGRESSION IN SEVERE ACUTE RESPIRATORY SYNDROME (SARS) 审中-公开
公开(公告)号：WO2021204770A1
公开(公告)日：2021-10-14
申请号：PCT/EP2021/058885
申请日：2021-04-06
申请人： B.R.A.H.M.S GMBH
发明人： EBMEYER, Stefan , KROP, Manne , ODARJUK, Jutta
IPC分类号： G01N33/569
摘要： The invention relates to a method for prognosing disease progression in a patient that has or is at risk of developing a severe acute respiratory syndrome (SARS), wherein the method comprises determining a level of pro-adrenomedullin (proADM) or fragment(s) thereof in a sample from the patient, wherein said level indicates the severity of SARS progression. The method is in some embodiments configured for use when a patient exhibits symptoms of a severe acute respiratory syndrome (SARS), a patient exhibits symptoms of infection with a SARS-virus, the patient is infected with a SARS-virus, such as a SARS-coronavirus, such as SARS-CoV2.

8. 发明申请

WO2019122089A1 ANTIBIOTIC THERAPY GUIDANCE BASED ON PRO-ADM 审中-公开
公开(公告)号：WO2019122089A1
公开(公告)日：2019-06-27
申请号：PCT/EP2018/086131
申请日：2018-12-20
申请人： B.R.A.H.M.S GMBH
发明人： WILSON, Darius
IPC分类号： G01N33/50 , G01N33/74
CPC分类号： G01N33/502 , G01N33/74 , G01N2333/585 , G01N2800/26 , G01N2800/52
摘要： The invention relates to a method for antibiotic therapy guidance, stratification and/or control in a patient suspected of having an infection. In particular, the method comprises providing a sample form said patient, determining a level of pro ADM or fragment(s) thereof in said sample, and wherein the level of pro ADM or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required. In a preferred embodiment of the invention, the method comprises additionally determining in a sample from said patient a level of PCT or fragment(s) thereof. Furthermore, the invention also relates to a kit for carrying out the method of the present invention.

9. 发明申请

WO2019122088A1 ANTIBIOTIC THERAPY GUIDANCE BASED ON PROCALCITONIN IN PATIENTS WITH COMORBIDITIES 审中-公开
公开(公告)号：WO2019122088A1
公开(公告)日：2019-06-27
申请号：PCT/EP2018/086130
申请日：2018-12-20
申请人： B.R.A.H.M.S GMBH
发明人： WILSON, Darius , KIRSCH, Stefan
IPC分类号： G01N33/50 , G01N33/74
CPC分类号： G01N33/74 , G01N33/502 , G01N2333/585 , G01N2800/26 , G01N2800/52
摘要： The invention relates to a method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response and suspected of having an infection. The method also relates to a method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response, wherein the comorbidity is preferably selected from the group comprising metabolic disorder (obesity), diabetes, hypertension, renal disease, thrombosis, malignancy or cancer, and suspected of having an infection. In particular, the method comprises providing a sample from said patient and determining a level of PCT or fragment(s) thereof in said sample, wherein the level of PCT or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required. Furthermore, the invention also relates to a kit for carrying out the method of the present invention.

10. 发明申请

WO2019053124A1 PROADRENOMEDULLIN AS INDICATOR FOR RENAL REPLACEMENT THERAPY IN CRITICALLY ILL PATIENTS 审中-公开
公开(公告)号：WO2019053124A1
公开(公告)日：2019-03-21
申请号：PCT/EP2018/074735
申请日：2018-09-13
申请人： B.R.A.H.M.S GMBH
发明人： WILSON, Darius
IPC分类号： G01N33/50 , G01N33/68
摘要： The present invention relates to a method for assessing whether a critically ill subject is in need of a renal replacement therapy, wherein the method comprises determining in a sample obtained from said subject the level of proadrenomedullin (proADM) or a fragment thereof, preferably the fragment is MR-proADM, wherein said level of proADM or the fragment thereof is indicative of a need of said subject to receive a renal replacement therapy.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式